Anand Pharmatech Profile
Key Indicators
- Authorised Capital ₹ 0.75 M
as on 24-10-2024
- Paid Up Capital ₹ 0.11 M
as on 24-10-2024
- Company Age 28 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.00 M
as on 24-10-2024
- Revenue %
(FY 2023)
- Profit 11.36%
(FY 2023)
- Ebitda 30.80%
(FY 2023)
- Net Worth -60.31%
(FY 2023)
- Total Assets -3.51%
(FY 2023)
About Anand Pharmatech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.75 M and a paid-up capital of Rs 0.11 M.
The company currently has active open charges totaling ₹3.00 M.
Satyan Anand, Rajinder Raheja, Uttamjit Sabharwal, and One other member serve as directors at the Company.
- CIN/LLPIN
U24231CH1996PTC017706
- Company No.
017706
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Feb 1996
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Anand Pharmatech?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satyan Anand  | Director | 11-Mar-2005 | Current |
| Rajinder Raheja | Director | 24-Apr-2018 | Current |
| Uttamjit Sabharwal | Director | 24-Apr-2018 | Current |
| Amit Gupta | Director | 24-Apr-2018 | Current |
Financial Performance of Anand Pharmatech.
Anand Pharmatech Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 11.36% increase in profit. The company's net worth observed a substantial decline by a decrease of 60.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Anand Pharmatech?
In 2023, Anand Pharmatech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Amster Labs LimitedActive 11 months 30 daysSatyan Anand, Rajinder Raheja and 2 more are mutual person
- Evermark Developers And Promoters Private LimitedActive 4 years 2 months
Uttamjit Sabharwal is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 24 Feb 2016 | ₹3.00 M | Open |
How Many Employees Work at Anand Pharmatech?
Unlock and access historical data on people associated with Anand Pharmatech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Anand Pharmatech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Anand Pharmatech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
